Diagnostic services provider Unilabs and C2N Diagnostics, an Alzheimer’s disease (AD) and related neurological disorders-focused diagnostic firm, have partnered to advance brain health diagnostics and research across Europe and globally.
Under the multi-year partnership, both firms will expand access to C2N’s Precivity blood test portfolio across Europe, including Norway, Switzerland, and the UK.
Unilabs and C2N Diagnostics will also expand the test’s access in Peru, Saudi Arabia, and the United Arab Emirates.
C2N’s Precivity blood tests help healthcare providers and researchers detect amyloid plaques and tau tangles, key indicators of Alzheimer’s disease.
The test also guides medical management and treatment decisions.
As per the deal, C2N’s proprietary Alzheimer’s blood biomarkers will be transferred to Unilabs’ network across Europe. This will ensure that testing is performed with the same quality and accuracy as C2N’s central lab in St. Louis, Missouri, US.
Both companies anticipate this collaboration will advance Alzheimer’s diagnosis for patients with cognitive concerns or at high risk of related dementias.
Unilabs innovation head Rahul Chaudhary said: “This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionising early diagnosis, and research efforts and positively impacting long-term outcomes.
“C2N’s Precivity portfolio of blood tests and its innovative biomarker pipeline offers the highest performance precision tools in the industry.”
In 2020, the PrecivityAD blood test received the CE mark from the European Union and In Vitro Diagnostic Regulation legacy device status for commercial use.
Additionally, the UK’s Medicines and Healthcare Products Regulatory Agency approved PrecivityAD as an in vitro diagnostic to aid in diagnosing AD.
The PrecivityAD2 and PrecivityAD blood tests utilise advanced laboratory technologies to detect proteins in the blood associated with brain amyloid plaques.
Both partners anticipate that the Precivity portfolio will become available to Unilabs customers in various regions over the coming months.
C2NDiagnostics CEO Joel Braunstein said: “The sobering impact of Alzheimer’s disease reaches beyond any one country’s borders and that’s why it’s vital we respond to the global interest in our Precivity blood tests.”
Recently, C2N Diagnostics, which received around $15m from Eisai in March, announced positive accuracy results of its PrecivityAD2 test for AD diagnosis.
In June this year, the diagnostic company announced that Mayo Clinic Laboratories included the Precivity tests in its test offerings.
